SELLAS Life Sciences Group (SLS) Competitors $2.18 +0.01 (+0.23%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLS vs. DNA, AVXL, TNGX, ABUS, PVLA, URGN, GYRE, PRME, IOVA, and RZLTShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Ginkgo Bioworks (DNA), Anavex Life Sciences (AVXL), Tango Therapeutics (TNGX), Arbutus Biopharma (ABUS), Palvella Therapeutics (PVLA), Urogen Pharma (URGN), Gyre Therapeutics (GYRE), Prime Medicine (PRME), Iovance Biotherapeutics (IOVA), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. Its Competitors Ginkgo Bioworks Anavex Life Sciences Tango Therapeutics Arbutus Biopharma Palvella Therapeutics Urogen Pharma Gyre Therapeutics Prime Medicine Iovance Biotherapeutics Rezolute SELLAS Life Sciences Group (NASDAQ:SLS) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Does the media prefer SLS or DNA? In the previous week, SELLAS Life Sciences Group had 6 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 9 mentions for SELLAS Life Sciences Group and 3 mentions for Ginkgo Bioworks. SELLAS Life Sciences Group's average media sentiment score of 0.79 beat Ginkgo Bioworks' score of 0.15 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in SLS or DNA? 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 1.4% of SELLAS Life Sciences Group shares are held by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, SLS or DNA? SELLAS Life Sciences Group has a beta of 2.62, suggesting that its share price is 162% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Which has preferable valuation & earnings, SLS or DNA? SELLAS Life Sciences Group has higher earnings, but lower revenue than Ginkgo Bioworks. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences Group$1M273.30-$30.88M-$0.32-6.83Ginkgo Bioworks$227.04M4.12-$547.03M-$5.86-2.70 Do analysts rate SLS or DNA? SELLAS Life Sciences Group currently has a consensus target price of $7.00, indicating a potential upside of 220.37%. Ginkgo Bioworks has a consensus target price of $9.00, indicating a potential downside of 43.04%. Given SELLAS Life Sciences Group's stronger consensus rating and higher probable upside, equities analysts plainly believe SELLAS Life Sciences Group is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Ginkgo Bioworks 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Is SLS or DNA more profitable? SELLAS Life Sciences Group has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -136.56%. Ginkgo Bioworks' return on equity of -43.25% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -132.51% -92.79% Ginkgo Bioworks -136.56%-43.25%-22.29% SummarySELLAS Life Sciences Group beats Ginkgo Bioworks on 9 of the 15 factors compared between the two stocks. Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$272.05M$3.42B$6.16B$10.59BDividend YieldN/A2.30%5.73%4.78%P/E Ratio-6.8023.1085.6727.43Price / Sales273.30450.35584.77183.24Price / CashN/A46.1137.3961.86Price / Book16.8110.6812.516.79Net Income-$30.88M-$52.47M$3.32B$276.90M7 Day Performance15.30%1.08%707.60%0.29%1 Month Performance30.84%16.86%935.16%7.59%1 Year Performance74.80%16.25%2,403.40%39.41% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group1.8293 of 5 stars$2.19+0.2%$7.00+220.4%+81.7%$272.05M$1M-6.8010Options VolumeGap UpDNAGinkgo Bioworks1.1877 of 5 stars$13.20-2.4%$9.00-31.8%+102.5%$800.38M$230.82M-2.25640AVXLAnavex Life Sciences3.7245 of 5 stars$8.62-7.0%$44.00+410.4%+67.5%$796.24MN/A-15.1240TNGXTango Therapeutics1.2484 of 5 stars$8.47+18.6%$10.50+24.0%+37.8%$794.40M$42.07M-6.3790ABUSArbutus Biopharma1.1244 of 5 stars$4.28+4.1%$5.00+16.8%+8.8%$787.88M$6.17M-14.7690Negative NewsPVLAPalvella Therapeutics2.0354 of 5 stars$76.22+9.0%$75.50-0.9%N/A$773.07M$42.81M-6.30N/AURGNUrogen Pharma3.979 of 5 stars$16.76+0.5%$32.00+90.9%+41.0%$771.69M$90.40M-5.05200GYREGyre Therapeutics1.7316 of 5 stars$8.39+5.4%$17.00+102.6%-34.6%$766.65M$105.76M839.8440News CoveragePRMEPrime Medicine0.6395 of 5 stars$5.65-0.5%N/AN/A$764.38M$2.98M-3.62N/AIOVAIovance Biotherapeutics4.4926 of 5 stars$2.14+1.9%$11.90+456.1%-76.6%$759.89M$164.07M-1.74500RZLTRezolute2.4431 of 5 stars$8.07-2.4%$14.50+79.7%+86.7%$751.15MN/A-8.3240 Related Companies and Tools Related Companies Ginkgo Bioworks Alternatives Anavex Life Sciences Alternatives Tango Therapeutics Alternatives Arbutus Biopharma Alternatives Palvella Therapeutics Alternatives Urogen Pharma Alternatives Gyre Therapeutics Alternatives Prime Medicine Alternatives Iovance Biotherapeutics Alternatives Rezolute Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLS) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredWhat the hell is going on, America?America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
